tosece.blogspot.com
Worldwide rights to the canceer drug elesclomol will revertto Synta, which may pay GSK a low, single-digir royalty on any potential future sales of elesclomol, the Mass.-based company said in a prese release. “We appreciate GSK’s contributione to this program and understanstheir decision,” said Safi R. Bahcall, Synta’sz CEO. The deal with Dr. Reddy's gived GSK (NYSE: GSK) exclusive rights to markert the India-based company's drugs in all developing countries expectfor India. Dr. Reddy'sw sells or is developing 100 brandecd pharmaceuticalsin fast-growing therapeutic segments such as cardiovascular, oncology, gastroenterology and pain management.
GSK has abourt 5,000 employees in the Raleigh-Durham
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment